| Attribute |
Value |
| 52 Week Change |
-0.22685188 |
| Address1 |
1,000 N. West Street |
| Address2 |
Suite 1200 |
| All Time High |
70.8 |
| All Time Low |
0.79 |
| Ask |
1.71 |
| Ask Size |
5 |
| Audit Risk |
8 |
| Average Analyst Rating |
1.1 - Strong Buy |
| Average Daily Volume10 Day |
1,285,510 |
| Average Daily Volume3 Month |
1,989,801 |
| Average Volume |
1,989,801 |
| Average Volume10Days |
1,285,510 |
| Beta |
0.864 |
| Bid |
1.64 |
| Bid Size |
17 |
| Board Risk |
8 |
| Book Value |
1.017 |
| City |
Wilmington |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
9 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
1.67 |
| Current Ratio |
21.698 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,774,915,200 |
| Day High |
1.8 |
| Day Low |
1.63 |
| Display Name |
Inhibikase Therapeutics |
| Earnings Call Timestamp End |
1,723,723,200 |
| Earnings Call Timestamp Start |
1,723,723,200 |
| Earnings Timestamp |
1,774,555,200 |
| Earnings Timestamp End |
1,778,702,400 |
| Earnings Timestamp Start |
1,778,702,400 |
| Ebitda |
-45,887,728 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-2.307 |
| Enterprise Value |
105,841,200 |
| Eps Current Year |
-0.37 |
| Eps Forward |
-0.38 |
| Eps Trailing Twelve Months |
-0.49 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
1.8048 |
| Fifty Day Average Change |
-0.13480008 |
| Fifty Day Average Change Percent |
-0.07468976 |
| Fifty Two Week Change Percent |
-22.685188 |
| Fifty Two Week High |
2.365 |
| Fifty Two Week High Change |
-0.69500005 |
| Fifty Two Week High Change Percent |
-0.29386893 |
| Fifty Two Week Low |
1.33 |
| Fifty Two Week Low Change |
0.3399999 |
| Fifty Two Week Low Change Percent |
0.25563902 |
| Fifty Two Week Range |
1.33 - 2.365 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,608,733,800,000 |
| Float Shares |
85,419,062 |
| Forward Eps |
-0.38 |
| Forward P E |
-4.394737 |
| Free Cashflow |
-9,559,039 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
35 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,775,001,600 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.06421 |
| Held Percent Institutions |
0.80237997 |
| Implied Shares Outstanding |
132,032,636 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,020-12-23 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,688,083,200 |
| Last Split Factor |
1:6 |
| Long Business Summary |
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware. |
| Long Name |
Inhibikase Therapeutics, Inc. |
| Market |
us_market |
| Market Cap |
220,494,496 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_113910012 |
| Most Recent Quarter |
1,767,139,200 |
| Net Income To Common |
-48,259,188 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
220,494,502 |
| Number Of Analyst Opinions |
8 |
| Open |
1.79 |
| Operating Cashflow |
-27,786,464 |
| Operating Margins |
0.0 |
| Overall Risk |
9 |
| Payout Ratio |
0.0 |
| Phone |
302 295 3800 |
| Previous Close |
1.81 |
| Price Eps Current Year |
-4.5135136 |
| Price Hint |
4 |
| Price To Book |
1.6420846 |
| Profit Margins |
0.0 |
| Quick Ratio |
21.536 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.125 |
| Region |
US |
| Regular Market Change |
-0.14 |
| Regular Market Change Percent |
-7.73481 |
| Regular Market Day High |
1.8 |
| Regular Market Day Low |
1.63 |
| Regular Market Day Range |
1.63 - 1.8 |
| Regular Market Open |
1.79 |
| Regular Market Previous Close |
1.81 |
| Regular Market Price |
1.67 |
| Regular Market Time |
1,776,801,601 |
| Regular Market Volume |
2,584,265 |
| Return On Assets |
-0.20527 |
| Return On Equity |
-0.36044997 |
| Sand P52 Week Change |
0.3140242 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
9 |
| Shares Outstanding |
132,032,636 |
| Shares Percent Shares Out |
0.13069999 |
| Shares Short |
17,261,276 |
| Shares Short Previous Month Date |
1,772,150,400 |
| Shares Short Prior Month |
16,041,114 |
| Short Name |
Inhibikase Therapeutics, Inc. |
| Short Percent Of Float |
0.2291 |
| Short Ratio |
9.92 |
| Source Interval |
15 |
| State |
DE |
| Symbol |
IKT |
| Target High Price |
8.0 |
| Target Low Price |
3.0 |
| Target Mean Price |
5.75 |
| Target Median Price |
5.5 |
| Total Cash |
178,764,032 |
| Total Cash Per Share |
1.049 |
| Total Debt |
0 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-0.49 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
1.6991 |
| Two Hundred Day Average Change |
-0.02910006 |
| Two Hundred Day Average Change Percent |
-0.01712675 |
| Type Disp |
Equity |
| Volume |
2,584,265 |
| Website |
https://www.inhibikase.com |
| Zip |
19,801 |